MSLE logo

SATELLOS BIOSCIENCE INC

MSLENASDAQ
🏆 #4969 by market capEarnings Nov 3US Equity
$8.60▼ $0.20 (−2.38%)
🌙 After hours$8.60▼ 0.01%Regular close · extended-hours price shown
🔔
Track MSLE
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.4%
7d▼ 3.3%
14d▼ 13.0%
30d▼ 3.5%
ytd—
1y—
🏦Market Cap
$11M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$8.56 – $8.74
52-Week Range
$5.30 – $13.40
Volume
$1.73B
Avg Volume
$2.26B
Shares Outstanding
1.3M
Next Earnings
Nov 30, 2026

Fundamentals Snapshot

Annual Revenue
$808,679
Last Q Revenue
$200,290
P/E Ratio
-4.5
P/S Ratio
0.0x
EPS (TTM)
$-1.68
Dividend Yield
0.00%
Dilution (1yr)
+11.9%

Why Investors Own MSLE

  • ✓High-growth profile — revenue up +17.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 67% gross margin and 6% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MSLE logo

SATELLOS BIOSCIENCE INC

MSLE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$26M▲ +36.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$24M▲ +35.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
15.5M▲ +11.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$10M▼ −$30M YoY
StockOtter · stockotter.space

About SATELLOS BIOSCIENCE INC

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Ratings

ⓘ
Consensus
Buy
11 analysts
Strong Buy4
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

Defense World·1d ago

Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Rated “Moderate Buy” by Wall Street Brokerages

Shares of Satellos Bioscience Inc. (NASDAQ: MSLE - Get Free Report) have received an average rating of "Moderate Buy" from the seven brokerages that are presently covering the firm, MarketBeat.com reports. One analyst ha

Benzinga·Jul 8

Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence

Recently listed, Satellos Bioscience Inc. (NASDAQ:MSLE) on Wednesday reported six-month interim data from its ongoing TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy (DMD)